{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-002360","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.275067+00:00","generated_at":"2026-06-07T01:36:29.453141+00:00","sec_items":["1.01","2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aditxt subsidiary Pearsanta acquires MDNA's Mitomic testing platform for ~$25M","bullets":["Consideration: 50k shares of ADTX common, warrants for 50k shares, 5k Pearsanta preferred ($25M value), up to $3.2M in transition services.","Amendments to asset purchase agreement removed $500k upfront and $500k closing payments; increased transition services cap from $2.2M to $3.2M.","Platform includes Mitomic Endometriosis Test (blood-based) and Mitomic Prostate Test; pipeline for ovarian, lung, pancreatic, and other cancers.","Also amended Merger Agreement with Evofem to extend proxy statement filing deadline to February 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-002360","json":"https://secwatch.observer/filing/0001213900-24-002360.json","markdown":"https://secwatch.observer/filing/0001213900-24-002360.md","text":"https://secwatch.observer/filing/0001213900-24-002360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390024002360/0001213900-24-002360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390024002360/ea191392-8k425_aditxtinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:36:29.453141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5dea38ff4841cd0be18e56d47eac5c58c178b7e","claim":"Aditxt, Inc. completed an acquisition involving MDNA Life Sciences, Inc. for the Company completed its acquisition of the Acquired Assets and issued to MDNA the Company Common Stock, the Company Warrants and the Pearsanta Preferred Stock (closed 2024-01-04).","evidence_excerpt":"On January 4, 2024 (the “ Closing Date ”), the Company completed its acquisition of the Acquired Assets and issued to MDNA the Company Common Stock, the Company Warrants and the Pearsanta Preferred Stock.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390024002360/0001213900-24-002360-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"MDNA Life Sciences, Inc."},{"label":"Consideration","value":"the Company completed its acquisition of the Acquired Assets and issued to MDNA the Company Common Stock, the Company Warrants and the Pearsanta Preferred Stock"},{"label":"Closing","value":"2024-01-04"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}